← Eichor
Condition: Large Cell Neuroendocrine Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Large Cell Neuroendocrine Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phase 1/Phase 2 · 15 location(s) · Phanes Therapeutics · NCT05652686Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Phase 1/Phase 2 · 2 location(s) · University of Arizona · NCT06814496A Study of FZ-AD005 in Patients With Advanced Solid Tumors
Phase 1 · 3 location(s) · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · NCT06424665Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
Phase 1 · 20 location(s) · SystImmune Inc. · NCT07080242Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic P
Phase 3 · 40 location(s) · Intergroupe Francophone de Cancerologie Thoracique · NCT06937905FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum
Phase 2 · 31 location(s) · Centre Leon Berard · NCT06393816Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06228066A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients
Phase 1 · 16 location(s) · OncoNano Medicine, Inc. · NCT06022029Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix
Phase N/A · 1 location(s) · M.D. Anderson Cancer Center · NCT04723095Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)
Phase N/A · 2 location(s) · Oncology Center of Biochemical Education And Research · NCT06717243Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Sol
Phase 1/Phase 2 · 5 location(s) · Molecular Partners AG · NCT07278479Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
NA · 1 location(s) · Cedars-Sinai Medical Center · NCT04907643Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06176989Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)
Phase 2 · 15 location(s) · Gruppo Oncologico Italiano di Ricerca Clinica · NCT06418087A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06406465Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabo
Phase 2 · 582 location(s) · National Cancer Institute (NCI) · NCT03866382Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Phase 1 · 7 location(s) · Novartis Pharmaceuticals · NCT07006727
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.